Researchers discover intake of FDA-approved drug modulates disease progression in Alzheimer’s disease model

The study, recently published in Science Translational Medicine, investigates how niacin modulates microglia response to amyloid plaques in an Alzheimer's disease animal model.

Gary Landreth, PhD, Martin Professor of Alzheimer's Research, and Miguel Moutinho, PhD, postdoctoral fellow in Anatomy, Cell Biology and Physiology, led the study.

"This study identifies a potential novel therapeutic target for Alzheimer's disease, which can be modulated by FDA-approved drugs," Moutinho said. "The translational potential of this strategy to clinical use is high."

Niacin, which sustains metabolism throughout the body, is mainly obtained through a typical diet; it also can be taken in supplements and cholesterol-lowering drugs. The brain, however, Moutinho found, uses niacin in a different manner.

In the brain, niacin interacts with a highly-selective receptor, HCAR2, present in immune cells physically associated with amyloid plaques. When niacin -- used in this project as the FDA-approved Niaspan drug -- activates the receptor, it stimulates beneficial actions from these immune cells, Landreth said.

"After the Alzheimer's disease animal models received niacin, they ended up with fewer plaques and they have improved cognition," Landreth said, "and we directly showed that these actions were due to the HCAR2 receptor."

Past epidemiology studies of niacin and Alzheimer's disease showed that people who had higher levels of niacin in their diet had diminished risk of the disease, Landreth said. Niacin is also currently being used in clinical trials in Parkinson's disease and glioblastoma.

To further their research into niacin and the brain, Landreth and Moutinho are collaborating with Jared Brosch, MD, associate professor of clinical neurology, who is applying for a clinical pilot trial to study the affects of niacin and the human brain.